# Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

> **NCT07165951** · PHASE3 · RECRUITING · sponsor: **Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.** · enrollment: 566 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** TQB2868 Injection
- **DRUG:** Anlotinib Hydrochloride Capsules
- **DRUG:** Gemcitabine Hydrochloride Injection
- **DRUG:** Paclitaxel for Injection
- **DRUG:** TQB2868 Placebo

## Key facts

- **NCT ID:** NCT07165951
- **Lead sponsor:** Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2028-05
- **Final completion:** 2028-12
- **Target enrollment:** 566 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07165951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07165951, "Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07165951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*